Fractyl Health (GUTS) priced its IPO at the $15.00 mid-point of its $14.00-to-$16.00 range – and kept the deal’s size at the 7.33 million shares in the prospectus – to raise $109.95 million on Thursday night, Feb. 1, 2024. The metabolic therapeutics company is targeting obesity and Type 2 diabetes. The stock dropped below its […]
February 1, 2024 Read MoreAlto Neuroscience (ANRO) priced its upsized IPO at $16.00 – the high end of its $14.00-to-$16.00 range. The company increased the deal’s size to 8.04 million shares – up from 6.7 million shares in the prospectus – and raised $128.64 million on Thursday night, Feb. 1, 2024. The Phase 2 clinical biotech is developing drugs […]
Read MoreAmer Sports (AS) priced its IPO at $13.00 – $3.00 below its $16.00-to-$18.00 range – and increased the deal’s size to 105.0 million shares – up from 100.0 million in the prospectus. The IPO raised $1.37 billion ($1,365.0 million) on Wednesday night, Jan. 31, 2024. Amer Sports is the parent of three big iconic brands, including […]
Read MoreTwo biotechs – Alto Neuroscience and Fractyl Health – pumped some warm air into the chilly February IPO Calendar early today. Both companies disclosed IPO terms in S-1/A filings early Monday morning, Jan. 29, 2024. Both IPOs are set for pricing Thursday night, Feb. 1, 2024, to trade Friday, Feb. 2, 2024: Alto Neuroscience (ANRO […]
January 29, 2024 Read MoreMore stock at the mid-point: That’s how lung cancer biotech ArriVent BioPharma (AVBP) played it when pricing its IPO on Thursday night (Jan 25, 2024). ArriVent BioPharma increased the IPO’s size to 9.72 million shares – up from 8.33 million shares in the prospectus – and priced the deal at $18.00 – the mid-point of […]
January 26, 2024 Read MoreKKR-backed BrightSpring Health Services (BTSG) priced its IPO at $13.00 – $2.00 below the bottom of its range – on Thursday night (Jan. 25, 2024). BrightSpring’s stock opened at $12.00 – down $1.00 from its IPO price – at 1:16 p.m. EST on the NASDAQ today – Friday, Jan. 26, 2024 – on volume of […]
Read MoreCG Oncology (CGON) – the first biotech IPO of the year – scored a moonshot today in its NASDAQ debut. The bladder cancer biotech doubled its $19.00 IPO price – rising to $38.00 shortly after 3 p.m. EST today (Thursday, Jan. 25, 2024). A moonshot occurs when a company doubles its IPO stock price – […]
January 25, 2024 Read MoreTwice: Bladder cancer biotech CG Oncology (CGON) upsized its IPO for the second time this week – by pricing 20.0 million shares at $19.00 – $1.00 above the top of its range – to raise $380.0 million on Wednesday night (Jan. 24, 2024). This is the first biotech IPO of the year – and the […]
January 24, 2024 Read MoreTwo Hong Kong companies – J-Long Group (JL) and SU Group Holdings (SUGP) – priced their small IPOs on Tuesday night (Jan. 23, 2024): –J-Long Group (JL) priced its IPO in sync with the terms in its prospectus – 1.4 million shares at $5.00 – the mid-point of its $4.00-to-$6.00 range – to raise $7.0 million. Eddid […]
January 23, 2024 Read MoreSomeone involved in this deal must like the number 17: Bladder cancer biotech CG Oncology (CGON Proposed) upsized its IPO to 17 million shares – up from 11.8 million shares originally – and kept the price range at $16.00 to $18.00. If the upsized IPO is priced at the $17.00 mid-point, CG Oncology will raise $289.0 million – […]
Read More